158 related articles for article (PubMed ID: 37581487)
1. From Failure to Meet the Clinical Endpoint to U.S. Food and Drug Administration Approval: 15th Antisense Oligonucleotide Therapy Approved Qalsody (Tofersen) for Treatment of
van Roon-Mom W; Ferguson C; Aartsma-Rus A
Nucleic Acid Ther; 2023 Aug; 33(4):234-237. PubMed ID: 37581487
[No Abstract] [Full Text] [Related]
2. Tofersen: First Approval.
Blair HA
Drugs; 2023 Jul; 83(11):1039-1043. PubMed ID: 37316681
[TBL] [Abstract][Full Text] [Related]
3. Profiling tofersen as a treatment of superoxide dismutase 1 amyotrophic lateral sclerosis.
Oliveira Santos M; de Carvalho M
Expert Rev Neurother; 2024 Jun; 24(6):549-553. PubMed ID: 38758193
[TBL] [Abstract][Full Text] [Related]
4. Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for
Miller T; Cudkowicz M; Shaw PJ; Andersen PM; Atassi N; Bucelli RC; Genge A; Glass J; Ladha S; Ludolph AL; Maragakis NJ; McDermott CJ; Pestronk A; Ravits J; Salachas F; Trudell R; Van Damme P; Zinman L; Bennett CF; Lane R; Sandrock A; Runz H; Graham D; Houshyar H; McCampbell A; Nestorov I; Chang I; McNeill M; Fanning L; Fradette S; Ferguson TA
N Engl J Med; 2020 Jul; 383(2):109-119. PubMed ID: 32640130
[TBL] [Abstract][Full Text] [Related]
5. Neurofilament light-chain response during therapy with antisense oligonucleotide tofersen in SOD1-related ALS: Treatment experience in clinical practice.
Meyer T; Schumann P; Weydt P; Petri S; Koc Y; Spittel S; Bernsen S; Günther R; Weishaupt JH; Dreger M; Kolzarek F; Kettemann D; Norden J; Boentert M; Vidovic M; Meisel C; Münch C; Maier A; Körtvélyessy P
Muscle Nerve; 2023 Jun; 67(6):515-521. PubMed ID: 36928619
[TBL] [Abstract][Full Text] [Related]
6. Trial of Antisense Oligonucleotide Tofersen for
Miller TM; Cudkowicz ME; Genge A; Shaw PJ; Sobue G; Bucelli RC; Chiò A; Van Damme P; Ludolph AC; Glass JD; Andrews JA; Babu S; Benatar M; McDermott CJ; Cochrane T; Chary S; Chew S; Zhu H; Wu F; Nestorov I; Graham D; Sun P; McNeill M; Fanning L; Ferguson TA; Fradette S;
N Engl J Med; 2022 Sep; 387(12):1099-1110. PubMed ID: 36129998
[TBL] [Abstract][Full Text] [Related]
7. Breaking barriers with tofersen: Enhancing therapeutic opportunities in amyotrophic lateral sclerosis.
Saini A; Chawla PA
Eur J Neurol; 2024 Feb; 31(2):e16140. PubMed ID: 37975798
[TBL] [Abstract][Full Text] [Related]
8. Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study.
Benatar M; Wuu J; Andersen PM; Bucelli RC; Andrews JA; Otto M; Farahany NA; Harrington EA; Chen W; Mitchell AA; Ferguson T; Chew S; Gedney L; Oakley S; Heo J; Chary S; Fanning L; Graham D; Sun P; Liu Y; Wong J; Fradette S
Neurotherapeutics; 2022 Jul; 19(4):1248-1258. PubMed ID: 35585374
[TBL] [Abstract][Full Text] [Related]
9. [SOD1 gene therapy delays ALS disease progression].
Forsberg K; Karlsborg M; Salvesen L; Svenstrup K; Winroth I; Berntsson H; M Andersen P
Lakartidningen; 2024 Apr; 121():. PubMed ID: 38666665
[TBL] [Abstract][Full Text] [Related]
10. ALS antisense drug falters in phase III.
Mullard A
Nat Rev Drug Discov; 2021 Dec; 20(12):883-885. PubMed ID: 34716445
[No Abstract] [Full Text] [Related]
11. Myelitis as a side effect of tofersen therapy in SOD1-associated ALS.
Reilich P; Schöberl F; Hiebeler M; Tonon M; Ludolph AC; Senel M
J Neurol; 2024 Apr; 271(4):2114-2118. PubMed ID: 38066205
[No Abstract] [Full Text] [Related]
12. Inclusions in macrophages of the cerebrospinal fluid during treatment with Tofersen.
Sparasci D; Castelli C; Staedler C; Gobbi C; Ripellino P
Muscle Nerve; 2023 Feb; 67(2):E3-E5. PubMed ID: 36477882
[No Abstract] [Full Text] [Related]
13. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study.
Miller TM; Pestronk A; David W; Rothstein J; Simpson E; Appel SH; Andres PL; Mahoney K; Allred P; Alexander K; Ostrow LW; Schoenfeld D; Macklin EA; Norris DA; Manousakis G; Crisp M; Smith R; Bennett CF; Bishop KM; Cudkowicz ME
Lancet Neurol; 2013 May; 12(5):435-42. PubMed ID: 23541756
[TBL] [Abstract][Full Text] [Related]
14. RNase-H-mediated silencing in the CNS proves predictably nontrivial.
Moazami MP; Wood MJA
Med; 2022 Nov; 3(11):733-734. PubMed ID: 36370693
[TBL] [Abstract][Full Text] [Related]
15. Silence superoxide dismutase 1 (SOD1): a promising therapeutic target for amyotrophic lateral sclerosis (ALS).
Abati E; Bresolin N; Comi G; Corti S
Expert Opin Ther Targets; 2020 Apr; 24(4):295-310. PubMed ID: 32125907
[No Abstract] [Full Text] [Related]
16. Enhancing Clinical Infrastructure for the Delivery of Intrathecal and Genetic Therapies: A Qalsody (Tofersen) Model for Patients With
Morganroth J; Bardakjian TM; Dratch L; Quinn CC; Elman LB
Neurol Clin Pract; 2024 Aug; 14(4):e200303. PubMed ID: 38855716
[TBL] [Abstract][Full Text] [Related]
17. [Gene-specific treatment approaches in amyotrophic lateral sclerosis in the present and future].
Brenner D; Freischmidt A; Ludolph AC; Weishaupt JH
Nervenarzt; 2020 Apr; 91(4):287-293. PubMed ID: 32076756
[TBL] [Abstract][Full Text] [Related]
18. Promise of Nucleic Acid Therapeutics for Amyotrophic Lateral Sclerosis.
Ito D
Ann Neurol; 2022 Jan; 91(1):13-20. PubMed ID: 34704267
[TBL] [Abstract][Full Text] [Related]
19. ASO drug Qalsody (tofersen) targets amyotrophic lateral sclerosis.
Jin J; Zhong XB
Trends Pharmacol Sci; 2023 Dec; 44(12):1043-1044. PubMed ID: 37709589
[TBL] [Abstract][Full Text] [Related]
20. Tofersen (Qalsody) for ALS.
Med Lett Drugs Ther; 2023 Jul; 65(1681):113-114. PubMed ID: 37460141
[No Abstract] [Full Text] [Related]
[Next] [New Search]
